[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 05/12/2017 include:

1. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.72
2. $FLKS – Flex Pharma Inc :
   1. Book/sh = $3.57
3. $KTOV – Kitov Pharmaceuticals Holdings Ltd :
   1. Book/sh = $1.80
4. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $1.31
5. $OREX – Orexigen Therapeutics, Inc. :
   1. Book/sh = $5.03
6. $RXII – RXi Pharmaceuticals Corp :
   1. Book/sh = $1.00
7. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $7.04
8. $TOPS – TOP SHIPS Inc :
   1. Book/sh = $9.83
9. $VICL – Vical Incorporated :
   1. Book/sh = $4.05

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) as of 05/12/2017 include

1. $AVGR – Avinger Inc :
   1. Cash/sh = $1.37
2. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $1.27
3. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $3.12
4. $OPHT – Ophthotech Corp :
   1. Cash/sh = $7.94
5. $OREX – Orexigen Therapeutics, Inc. :
   1. Cash/sh = $5.19
6. $QURE – Uniqure NV :
   1. Cash/sh = $5.37
7. $TEAR – TearLab Corp :
   1. Cash/sh = $2.77
8. $TNDM – Tandem Diabetes Care Inc :
   1. Cash/sh = $1.06
9. $VICL – Vical Incorporated :
   1. Cash/sh = $3.45

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 05/15/2017 – 05/19/2017:

1) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.96
b. Sell at >~ $5.80

2) GNMX – Medgenics Inc
a. Buy at < ~ $1.30
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

3) CTRV – ContraVir Pharmaceuticals Inc
a. Buy at < ~ $0.62
b. Sell at >~ $1.25
c. Catalysts:
1. Phase 2, Multiple Ascending Dose Proof of Concept Study; 20170601; 20170930; https://clinicaltrials.gov/ct2/show/NCT02710604?term=CONTRAVIR&rank=1
2. A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia; 20171231; 20181231; https://clinicaltrials.gov/ct2/show/NCT02412917?term=CONTRAVIR&rank=3

4) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at < ~ $0.62
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

5) ONTX – Onconova Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $2.00
b. Sell at >~ $3.45
c. Catalysts:
1. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following “subgroup analyses” and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm

6) GALE – Galena Biopharma Inc
a. Buy at < ~ $0.53
b. Sell at >~ $0.79
c. Catalysts:
1. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b DSMB expects to perform the interim efficacy analysis near the end of 2017; 20171115; 20171231; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
2. NeuVax™ + trastuzumab, HER2 1+,2+ Phase 2b Completion of enrollment is expected in the second quarter of 2017; 20170515; 20170630; https://www.galenabiopharma.com/pipeline/neuvax-nelipepimut-s/neuvax-trastuzumab-her2-1-2/default.aspx
3. Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients (HER3+); 20191231; 20201231; https://clinicaltrials.gov/ct2/show/NCT02297698?term=neuvax&rank=1
4. Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer; 20190301; 20190331; https://clinicaltrials.gov/ct2/show/NCT02636582?term=NCT02636582&rank=1

7) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.17
b. Sell at >~ $2.45

8) SRNE – Sorrento Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $1.55
b. Sell at >~ $2.10
c. Catalysts:
1. STI-001 regulatory pathway and discussions with FDA in 2017; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
2. Potential LA Cell (iTAb) partnership; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
3. Biosimilars Erbitux 1.2Billion Remicade 6.6Billion Xolair 0.8Billion – combined huge market potential; FDA in 1H’17; 20170101; 20170630; https://twitter.com/DrSManian
4. STI-A1014 PD-L1 mAb IND filing in 2017 in CN; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
5. IND filing for c-MET ADC expected in 2017 / 2018; 20170701; 20181231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
6. AntiPD1 Antibody – big licensing deal with Servier – will be in clinic 2H 2017; 20170701; 20171231; https://twitter.com/DrSManian
7. 3 clinical programs in 2017 w/ promising human & in vivo proof-of-concept data; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 05/15/2017 – 05/19/2017, and Why?

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) as of 05/05/2017 include:

1. $AVIR – Aviragen Therapeutics Inc :
   1. Book/sh = $0.72
2. $DMTX – Dimension Therapeutics Inc :
   1. Book/sh = $2.40
3. $FLKS – Flex Pharma Inc :
   1. Book/sh = $3.57
4. $KTOV – Kitov Pharmaceuticals Holdings Ltd :
   1. Book/sh = $1.80
5. $NVGN – Novogen Limited (ADR) :
   1. Book/sh = $1.31
6. $OREX – Orexigen Therapeutics, Inc. :
   1. Book/sh = $5.03
7. $PRTO – Proteon Therapeutics Inc :
   1. Book/sh = $2.32
8. $TNXP – Tonix Pharmaceuticals Holding Corp. :
   1. Book/sh = $7.04
9. $TOPS – TOP SHIPS Inc :
   1. Book/sh = $9.83
10. $VICL – Vical Incorporated :
    1. Book/sh = $4.05

Please also Share Your Favorite Stocks currently Trading Below Book (TBB) here in this Topic as well, ok?

#StockPicks #Stock #Market #Trading

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) as of 05/05/2017 include:

1. $AVIR – Aviragen Therapeutics Inc :
   1. Cash/sh = $1.27
2. $DMTX – Dimension Therapeutics Inc :
   1. Cash/sh = $3.12
3. $OPHT – Ophthotech Corp :
   1. Cash/sh = $7.94
4. $PRTO – Proteon Therapeutics Inc :
   1. Cash/sh = $2.56
5. $TNDM – Tandem Diabetes Care Inc :
   1. Cash/sh = $1.06
6. $VICL – Vical Incorporated :
   1. Cash/sh = $3.45

Please also Share Your Favorite Stocks currently Trading Below Cash (TBC) here in this Topic as well, ok?

#StockPicks #Stock #Market #Trading

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 05/08/2017 – 05/12/2017:

1) GALE – Galena Biopharma Inc
a. Buy at < ~ $0.53
b. Sell at >~ $3.15
c. Catalysts:
1. Q1 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170508; 20170508; https://www.google.com/finance?q=GALE

2) AVGR – Avinger Inc – Trading Below Cash
a. Buy at < ~ $0.46
b. Sell at >~ $1.50
c. Catalysts:
1. In-Stent Restenosis Trial final results are expected to be released by the end of June 2017; 20170601; 20170630; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
2. The Company expects to file a 510(k) application for Pantheris 3.0 during the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
3. 510(k) application for this Pantheris BTK device in the fourth quarter of 2017; 20171001; 20172131; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html

3) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.96
b. Sell at >~ $5.80

4) GNMX – Medgenics Inc
a. Buy at < ~ $1.30
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

5) TEAR – TearLab Corp – Trading Below Cash
a. Buy at < ~ $1.85
b. Sell at >~ $3.80
c. Catalysts:
1. Brazil registration being prepared with approval expected in 2017; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ
2. New platform launch in 2017 will drive higher revenue and margins; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ

6) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at < ~ $0.62
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

7) AVEO – AVEO Pharmaceuticals, Inc.
a. Buy at < ~ $0.50
b. Sell at >~ $0.97
c. Catalysts:
1. Phase 3 enrollment to be completed June 2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170601; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
2. initial results from the Opdivo combination TiNivo study in RCC in the first half of 2017; 20170401; 20170630; https://seekingalpha.com/instablog/44479986-leny-hettmansperger/4974435-aveo-59c-insiders-recently-purchased-almost-10m-share-lots-significant-catalysts-upside-ahead?uprof=45&isDirectRoadblock=true
3. Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017. – Tivozanib + Opdivo – Renal cell cancer (RCC) – Phase 1/2; 20170630; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255714
4. Top-line data due 1Q 2018. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20180101; 20180331; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
5. Futility analysis due mid-2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170630; 20170930; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868

8) ONCS – OncoSec Medical Inc
a. Buy at < ~ $1.10
b. Sell at >~ $1.95
c. Catalysts:
1. The PISCES (Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study) Phase 2b clinical trial is planned to initiate in the first half of 2017; 20170228; 20170630; http://www.prnewswire.com/news-releases/oncosec-granted-fda-fast-track-designation-for-immunopulse-il-12-for-the-treatment-of-metastatic-melanoma-following-progression-on-pembrolizumab-or-nivolumab-300413726.html
2. Q3 2017 OncoSec Medical Inc Earnings Release (Estimated)
-; 20170607; 20170607; https://www.google.com/finance?q=ONCS

9) ONTX – Onconova Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $2.00
b. Sell at >~ $3.45
c. Catalysts:
1. Q1 2017 Onconova Therapeutics Inc Earnings Release (Estimated)
-; 20170509; 20170509; https://www.google.com/finance?q=ONTX
2. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following "subgroup analyses" and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm

10) RXII – RXi Pharmaceuticals Corp
a. Buy at < ~ $0.58
b. Sell at >~ $2.36
c. Catalysts:
1. Phase 2 first cohort data due 2Q 2017. Full data due 2H 2017. – Samcyprone – RXI-SCP-1502 – Cutaneous warts – Phase 2; 20170401; 20170630; http://investors.rxipharma.com/file/Index?KeyFile=37076476
2. Phase 2 final readout due mid 2017. – RXI-109-1402 – Connective tissue growth factor ( – Phase 2; 20170601; 20170731; http://investors.rxipharma.com/file/Index?KeyFile=37076476
3. Phase 2 enrollment to be completed early 2017. Safety data readout due 2H2017. – RXI-109-1501 – Retinal scarring – Phase 1/2; 20170701; 20171231; http://investors.rxipharma.com/file/Index?KeyFile=37076476

11) BDSI – BioDelivery Sciences International, Inc.
a. Buy at < ~ $1.55
b. Sell at >~ $2.15

12) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.17
b. Sell at >~ $2.45

13) QURE – Uniqure NV – Trading Below Cash
a. Buy at < ~ $4.91
b. Sell at >~ $8.30
c. Catalysts:
1. Uniqure NV at UBS Global Healthcare Conference; 20170522; 20170522; https://www.google.com/finance?q=QURE
2. Q1 2017 Uniqure NV Earnings Release (Estimated); 20170529; 20170529; https://www.google.com/finance?q=QURE

14) XENE – Xenon Pharmaceuticals Inc
a. Buy at < ~ $3.65
b. Sell at >~ $7.50
c. Catalysts:
1. Phase 2b clinical trial of TV-45070 topline results expected in mid-2017.; 20170401; 20170930; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
2. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
3. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
4. Q1 2017 Xenon Pharmaceuticals Inc Earnings Release (Estimated)
-; 20170508; 20170508; https://www.google.com/finance?q=XENE

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 05/08/2017 - 05/12/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 05/01/2017 – 05/05/2017:

1) GALE – Galena Biopharma Inc
a. Buy at < ~ $0.53
b. Sell at >~ $3.15
c. Catalysts:
1. Q1 2017 Galena Biopharma Inc Earnings Release (Estimated)
-; 20170508; 20170508; https://www.google.com/finance?q=GALE

2) AVGR – Avinger Inc – Trading Below Cash
a. Buy at < ~ $0.50
b. Sell at >~ $1.50
c. Catalysts:
1. In-Stent Restenosis Trial final results are expected to be released by the end of June 2017; 20170601; 20170630; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
2. The Company expects to file a 510(k) application for Pantheris 3.0 during the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
3. 510(k) application for this Pantheris BTK device in the fourth quarter of 2017; 20171001; 20172131; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html

3) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.96
b. Sell at >~ $5.80

4) GNMX – Medgenics Inc
a. Buy at < ~ $1.30
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

5) TEAR – TearLab Corp – Trading Below Cash
a. Buy at < ~ $1.85
b. Sell at >~ $3.80
c. Catalysts:
1. Brazil registration being prepared with approval expected in 2017; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ
2. New platform launch in 2017 will drive higher revenue and margins; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ

6) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at < ~ $0.62
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

7) AVEO – AVEO Pharmaceuticals, Inc.
a. Buy at < ~ $0.50
b. Sell at >~ $0.97
c. Catalysts:
1. Phase 3 enrollment to be completed June 2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170601; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
2. initial results from the Opdivo combination TiNivo study in RCC in the first half of 2017; 20170401; 20170630; https://seekingalpha.com/instablog/44479986-leny-hettmansperger/4974435-aveo-59c-insiders-recently-purchased-almost-10m-share-lots-significant-catalysts-upside-ahead?uprof=45&isDirectRoadblock=true
3. Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017. – Tivozanib + Opdivo – Renal cell cancer (RCC) – Phase 1/2; 20170630; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255714
4. Top-line data due 1Q 2018. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20180101; 20180331; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
5. Futility analysis due mid-2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170630; 20170930; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868

8) ONCS – OncoSec Medical Inc
a. Buy at < ~ $1.10
b. Sell at >~ $1.95
c. Catalysts:
1. The PISCES (Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study) Phase 2b clinical trial is planned to initiate in the first half of 2017; 20170228; 20170630; http://www.prnewswire.com/news-releases/oncosec-granted-fda-fast-track-designation-for-immunopulse-il-12-for-the-treatment-of-metastatic-melanoma-following-progression-on-pembrolizumab-or-nivolumab-300413726.html
2. Q3 2017 OncoSec Medical Inc Earnings Release (Estimated)
-; 20170607; 20170607; https://www.google.com/finance?q=ONCS

9) ONTX – Onconova Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $2.00
b. Sell at >~ $3.45
c. Catalysts:
1. Q1 2017 Onconova Therapeutics Inc Earnings Release (Estimated)
-; 20170509; 20170509; https://www.google.com/finance?q=ONTX
2. Original Phase 3 trial did not meet endpoint in Feb 2014. However, following "subgroup analyses" and lack of current treatment options a further Phase 3 trial was initiated in December 2015. Interim analysis due 2H 2017. Enrollment to be completed 1Q 2018. – IV Rigosertib – INSPIRE – 2nd-line HR-MDS (high risk myelodysplastic syndromes) – Phase 3; 20170701; 20171231; https://www.sec.gov/Archives/edgar/data/1130598/000110465916156981/a16-17154_110q.htm

10) BDSI – BioDelivery Sciences International, Inc.
a. Buy at < ~ $1.55
b. Sell at >~ $2.15

11) QURE – Uniqure NV – Trading Below Cash
a. Buy at < ~ $4.91
b. Sell at >~ $8.30
c. Catalysts:
1. Uniqure NV at UBS Global Healthcare Conference; 20170522; 20170522; https://www.google.com/finance?q=QURE
2. Q1 2017 Uniqure NV Earnings Release (Estimated); 20170529; 20170529; https://www.google.com/finance?q=QURE

12) RTTR – Ritter Pharmaceuticals Inc
a. Buy at < ~ $0.76
b. Sell at >~ $3.70
c. Catalysts:
1. end of phase 2 meeting with the company which is expected to take place in the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/ritter-pharmaceuticals-inc-announces-end-140000803.html
2. initiation of phase 3 in the first half of 2018; 20180101; 20180630; http://finance.yahoo.com/news/ritter-pharmaceuticals-inc-announces-end-140000803.html

13) XENE – Xenon Pharmaceuticals Inc
a. Buy at < ~ $3.65
b. Sell at >~ $7.50
c. Catalysts:
1. Phase 2b clinical trial of TV-45070 topline results expected in mid-2017.; 20170401; 20170930; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
2. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
3. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
4. Q1 2017 Xenon Pharmaceuticals Inc Earnings Release (Estimated)
-; 20170508; 20170508; https://www.google.com/finance?q=XENE

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 05/01/2017 - 05/05/2017, and Why?

[Michael DeVries]

Here’s some more IMHO Must Read Articles for Traders …

1. Three Ways to Move Forward as a Trader => http://traderfeed.blogspot.com/2017/04/three-ways-to-move-forward-as-trader.html
2. A Simple Mistake Traders Make => http://traderfeed.blogspot.com/2017/04/a-simple-mistake-traders-make.html
3. Three Best Practices of Currently Successful Traders => http://traderfeed.blogspot.com/2017/04/three-best-practices-of-currently.html

What do you all think about all of that?

I hope this helps! Good Luck! and Have a Great Day!

– Michael S. DeVries

[Michael DeVries]

#Bullish #Stocks currently #TradingBelowCash (#TBC) = $AVIR $DMTX $OPHT $PRTO $TNDM $TROV

#Bullish #Stocks currently #TradingBelowBook ( #TBB ) = $DMTX $NVGN $PRTO $TROV

#StockPicks #Stock #Market #Trades #Trading #TICKER

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 04/24/2017 – 04/28/2017:

1) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $3.15

2) AVGR – Avinger Inc – Trading Below Cash
a. Buy at < ~ $0.50
b. Sell at >~ $1.50
c. Catalysts:
1. In-Stent Restenosis Trial final results are expected to be released by the end of June 2017; 20170601; 20170630; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
2. The Company expects to file a 510(k) application for Pantheris 3.0 during the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
3. 510(k) application for this Pantheris BTK device in the fourth quarter of 2017; 20171001; 20172131; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html

3) ATEC – Alphatec Holdings Inc – Trading Below Cash
a. Buy at < ~ $1.96
b. Sell at >~ $5.80

4) GNMX – Medgenics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

5) TEAR – TearLab Corp – Trading Below Cash
a. Buy at < ~ $1.85
b. Sell at >~ $3.80
c. Catalysts:
1. Brazil registration being prepared with approval expected in 2017; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ
2. New platform launch in 2017 will drive higher revenue and margins; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ

6) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at < ~ $0.62
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

7) AVEO – AVEO Pharmaceuticals, Inc.
a. Buy at < ~ $0.50
b. Sell at >~ $0.97
c. Catalysts:
1. Phase 3 enrollment to be completed June 2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170601; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
2. initial results from the Opdivo combination TiNivo study in RCC in the first half of 2017; 20170401; 20170630; https://seekingalpha.com/instablog/44479986-leny-hettmansperger/4974435-aveo-59c-insiders-recently-purchased-almost-10m-share-lots-significant-catalysts-upside-ahead?uprof=45&isDirectRoadblock=true
3. Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017. – Tivozanib + Opdivo – Renal cell cancer (RCC) – Phase 1/2; 20170630; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255714
4. Top-line data due 1Q 2018. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20180101; 20180331; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
5. Futility analysis due mid-2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170630; 20170930; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868

8) ONCS – OncoSec Medical Inc
a. Buy at < ~ $1.10
b. Sell at >~ $1.95
c. Catalysts:
1. The PISCES (Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study) Phase 2b clinical trial is planned to initiate in the first half of 2017; 20170228; 20170630; http://www.prnewswire.com/news-releases/oncosec-granted-fda-fast-track-designation-for-immunopulse-il-12-for-the-treatment-of-metastatic-melanoma-following-progression-on-pembrolizumab-or-nivolumab-300413726.html

9) BDSI – BioDelivery Sciences International, Inc.
a. Buy at < ~ $1.55
b. Sell at >~ $2.15

10) QURE – Uniqure NV – Trading Below Cash
a. Buy at < ~ $5.15
b. Sell at >~ $8.30

11) RTTR – Ritter Pharmaceuticals Inc
a. Buy at < ~ $0.95
b. Sell at >~ $3.70
c. Catalysts:
1. end of phase 2 meeting with the company which is expected to take place in the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/ritter-pharmaceuticals-inc-announces-end-140000803.html
2. initiation of phase 3 in the first half of 2018; 20180101; 20180630; http://finance.yahoo.com/news/ritter-pharmaceuticals-inc-announces-end-140000803.html

12) XENE – Xenon Pharmaceuticals Inc
a. Buy at < ~ $3.65
b. Sell at >~ $7.50
c. Catalysts:
1. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
2. Phase 2b clinical trial of TV-45070 topline results expected in mid-2017.; 20170401; 20170930; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
3. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 04/24/2017 - 04/28/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 04/17/2017 – 04/21/2017:

1) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at <~ $0.53
b. Sell at >~ $3.15

2) AVGR – Avinger Inc – Trading Below Cash
a. Buy at <~ $0.50
b. Sell at >~ $1.50
c. Catalysts:
1. In-Stent Restenosis Trial final results are expected to be released by the end of June 2017; 20170601; 20170630; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
2. The Company expects to file a 510(k) application for Pantheris 3.0 during the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html
3. 510(k) application for this Pantheris BTK device in the fourth quarter of 2017; 20171001; 20172131; http://finance.yahoo.com/news/avinger-provides-strategic-200100859.html

3) GNMX – Medgenics Inc
a. Buy at <~ $1.50
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

4) TEAR – TearLab Corp – Trading Below Cash
a. Buy at <~ $1.85
b. Sell at >~ $3.80
c. Catalysts:
1. Brazil registration being prepared with approval expected in 2017; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ
2. New platform launch in 2017 will drive higher revenue and margins; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ

5) EARS – Auris Medical Holding AG – Trading Below Cash
a. Buy at <~ $0.62
b. Sell at >~ $1.50
c. Catalysts:
1. Phase 3 HEALOS data due 2H 2017. Reported September, 2016 that enrollment had reached halfway. – AM-111 HEALOS – Acute inner ear hearing loss – Phase 3; 20170701; 20171231; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
2. data from first AM-111 Phase 3 trial expected in Q3; 20170701; 20170930;
3. Phase 3 ASSENT data due 1H 2018. – AM-111 ASSENT – Acute inner ear hearing loss – Phase 3; 20180101; 20180630; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2221282
4. Phase 3 TACTT3 enrollment resumption announced January 26, 2017 with top-line results expected in early 2018. – AM-101 – TACTT3 – Acute inner ear tinnitus – Phase 3; 20180101; 20180331; http://ir.aurismedical.com/phoenix.zhtml?c=253572&p=irol-newsArticle&ID=2227813

6) AVEO – AVEO Pharmaceuticals, Inc.
a. Buy at <~ $0.50
b. Sell at >~ $0.97
c. Catalysts:
1. Phase 3 enrollment to be completed June 2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170601; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
2. initial results from the Opdivo combination TiNivo study in RCC in the first half of 2017; 20170401; 20170630; https://seekingalpha.com/instablog/44479986-leny-hettmansperger/4974435-aveo-59c-insiders-recently-purchased-almost-10m-share-lots-significant-catalysts-upside-ahead?uprof=45&isDirectRoadblock=true
3. Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017. – Tivozanib + Opdivo – Renal cell cancer (RCC) – Phase 1/2; 20170630; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255714
4. Top-line data due 1Q 2018. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20180101; 20180331; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
5. Futility analysis due mid-2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170630; 20170930; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868

7) ONCS – OncoSec Medical Inc
a. Buy at <~ $1.10
b. Sell at >~ $1.95
c. Catalysts:
1. The PISCES (Anti-PD-1 IL-12 Stage III/IV Combination Electroporation Study) Phase 2b clinical trial is planned to initiate in the first half of 2017; 20170228; 20170630; http://www.prnewswire.com/news-releases/oncosec-granted-fda-fast-track-designation-for-immunopulse-il-12-for-the-treatment-of-metastatic-melanoma-following-progression-on-pembrolizumab-or-nivolumab-300413726.html

8) MICT – Micronet Enertec Technologies Inc
a. Buy at <~ $1.12
b. Sell at >~ $1.58

9) RTTR – Ritter Pharmaceuticals Inc
a. Buy at <~ $0.95
b. Sell at >~ $3.70
c. Catalysts:
1. end of phase 2 meeting with the company which is expected to take place in the third quarter of 2017; 20170701; 20170930; http://finance.yahoo.com/news/ritter-pharmaceuticals-inc-announces-end-140000803.html
2. initiation of phase 3 in the first half of 2018; 20180101; 20180630; http://finance.yahoo.com/news/ritter-pharmaceuticals-inc-announces-end-140000803.html

10) TCON – TRACON Pharmaceuticals Inc
a. Buy at <~ $3.60
b. Sell at >~ $7.00
c. Catalysts:
1. Phase 2 data of TRC105 and Nexavar for Hepatocellular carcinoma due 2017; 20170101; 20171231; http://ir.traconpharma.com/phoenix.zhtml?c=253885&p=irol-newsArticle&ID=2169453
2. Small molecule inhibitor of mutated and wild-type Androgen Receptor • Expect Phase 1/2 dosing in 1H 2017; 20170401; 20170630; http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzczNTYwfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636270019327888891
3. PHASE 2 in GBM detailed data expected mid-2017; 20170401; 20170930; http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzczNTYwfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636270019327888891

11) XENE – Xenon Pharmaceuticals Inc
a. Buy at <~ $3.65
b. Sell at >~ $7.50
c. Catalysts:
1. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
2. Phase 2b clinical trial of TV-45070 topline results expected in mid-2017.; 20170401; 20170930; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
3. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 04/17/2017 – 04/21/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 04/10/2017 – 04/14/2017:

1) GALE – Galena Biopharma Inc – Trading Below Cash
a. Buy at < ~ $0.53
b. Sell at >~ $3.15

2) GNMX – Medgenics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

3) TEAR – TearLab Corp – Trading Below Cash
a. Buy at < ~ $1.85
b. Sell at >~ $3.80
c. Catalysts:
1. Brazil registration being prepared with approval expected in 2017; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ
2. New platform launch in 2017 will drive higher revenue and margins; 20170401; 20171231; https://www.tearlab.com/pdfs/Investor_Deck_April_12_2016.pdf&ved=0ahUKEwjBh7XJkIPTAhXDbxQKHamVCUkQFggfMAE&usg=AFQjCNEKRfW9rZ8OVqPr90z1BUdKJZogbw&sig2=wUP5_4hRdr5-LwiorihWxQ

4) AVEO – AVEO Pharmaceuticals, Inc.
a. Buy at < ~ $0.50
b. Sell at >~ $0.97
c. Catalysts:
1. Phase 3 enrollment to be completed June 2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170601; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
2. initial results from the Opdivo combination TiNivo study in RCC in the first half of 2017; 20170401; 20170630; https://seekingalpha.com/instablog/44479986-leny-hettmansperger/4974435-aveo-59c-insiders-recently-purchased-almost-10m-share-lots-significant-catalysts-upside-ahead?uprof=45&isDirectRoadblock=true
3. Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017. – Tivozanib + Opdivo – Renal cell cancer (RCC) – Phase 1/2; 20170630; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255714
4. Top-line data due 1Q 2018. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20180101; 20180331; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
5. Futility analysis due mid-2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170630; 20170930; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868

5) SRNE – Sorrento Therapeutics Inc
a. Buy at < ~ $2.90
b. Sell at >~ $4.67
c. Catalysts:
1. Potential LA Cell (iTAb) partnership; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
2. AntiPD1 Antibody – big licensing deal with Servier – will be in clinic 2H 2017; 20170701; 20171231; https://twitter.com/DrSManian
3. Biosimilars Erbitux 1.2Billion Remicade 6.6Billion Xolair 0.8Billion – combined huge market potential; FDA in 1H’17; 20170101; 20170630; https://twitter.com/DrSManian
4. STI-001 regulatory pathway and discussions with FDA in 2017; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
5. IND filing for c-MET ADC expected in 2017 / 2018; 20170701; 20181231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
6. 3 clinical programs in 2017 w/ promising human &
in vivo proof-of-concept data; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf
7. STI-A1014 PD-L1 mAb IND filing in 2017 in CN; 20170701; 20171231; http://sorrentotherapeutics.com/wp-content/uploads/2017/03/Sorrento-Corporate-Presentation-ROTH-Mar-2017-FINAL.pdf

6) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $1.65
b. Sell at >~ $2.50
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. European approvals expected during spring 2017 for indications ovarian cancer & metastatic breast cancer; 20170301; 20170630; http://stocktwits.com/message/77020751

7) MICT – Micronet Enertec Technologies Inc
a. Buy at < ~ $1.12
b. Sell at >~ $1.58

8) TCON – TRACON Pharmaceuticals Inc
a. Buy at < ~ $3.60
b. Sell at >~ $7.00
c. Catalysts:
1. Phase 2 data of TRC105 and Nexavar for Hepatocellular carcinoma due 2017; 20170101; 20171231; http://ir.traconpharma.com/phoenix.zhtml?c=253885&p=irol-newsArticle&ID=2169453
2. Small molecule inhibitor of mutated and wild-type Androgen Receptor • Expect Phase 1/2 dosing in 1H 2017; 20170401; 20170630; http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzczNTYwfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636270019327888891
3. PHASE 2 in GBM detailed data expected mid-2017; 20170401; 20170930; http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzczNTYwfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636270019327888891

9) TROV – TrovaGene Inc – Trading Below Cash
a. Buy at < ~ $0.90
b. Sell at >~ $1.50
c. Catalysts:
1. Phase II study planned with first patient to be dosed in 2017; 20170101; 20171231; https://seekingalpha.com/article/4058462-trovagene-trov-investor-presentation-slideshow

10) XENE – Xenon Pharmaceuticals Inc
a. Buy at < ~ $3.65
b. Sell at >~ $7.50
c. Catalysts:
1. Genentech anticipates initiating a Phase 2 clinical trial in 2017 for the potential treatment of pain; 20170101; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
2. Phase 2b clinical trial of TV-45070 topline results expected in mid-2017.; 20170401; 20170930; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828
3. Xenon expects to file an investigational new drug (IND) application in the fourth quarter of 2017; 20171001; 20171231; http://investor.xenon-pharma.com/phoenix.zhtml?c=253202&p=irol-newsArticle&ID=2234828

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 04/10/2017 – 04/14/2017, and Why?

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 04/03/2017 – 04/07/2017:

1) GALE – Galena Biopharma Inc
a. Buy at < ~ $0.53
b. Sell at >~ $3.15

2) TNDM – Tandem Diabetes Care Inc
a. Buy at < ~ $1.10
b. Sell at >~ $3.00

3) GNMX – Medgenics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

4) TKAI – Tokai Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $0.73
b. Sell at >~ $1.80
c. Catalysts:
1. Merger with Otic Pharma Ltd; 20170101; 20170630; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5
2. Merger may be terminated if the Otic Transaction is not consummated by April 30, 2017; 20170301; 20170430; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5

5) AVEO – AVEO Pharmaceuticals, Inc.
a. Buy at < ~ $0.50
b. Sell at >~ $0.97
c. Catalysts:
1. Phase 3 enrollment to be completed June 2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170601; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
2. initial results from the Opdivo combination TiNivo study in RCC in the first half of 2017; 20170401; 20170630; https://seekingalpha.com/instablog/44479986-leny-hettmansperger/4974435-aveo-59c-insiders-recently-purchased-almost-10m-share-lots-significant-catalysts-upside-ahead?uprof=45&isDirectRoadblock=true
3. Phase 1/2 initiation of dosing announced March 22, 2017. Phase 1 part of trial data due 1H 2017. – Tivozanib + Opdivo – Renal cell cancer (RCC) – Phase 1/2; 20170630; 20170630; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255714
4. Top-line data due 1Q 2018. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20180101; 20180331; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868
5. Futility analysis due mid-2017. – TIVO-3 – tivozanib – Third line treatment of patients with renal cell cancer – Phase 3; 20170630; 20170930; http://investor.aveooncology.com/phoenix.zhtml?c=219651&p=irol-newsArticle&ID=2255868

6) CYCC – Cyclacel Pharmaceuticals Inc
a. Buy at < ~ $3.15
b. Sell at >~ $5.60
c. Catalysts:
1. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
2. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3
3. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11

7) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $1.65
b. Sell at >~ $2.50
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. European approvals expected during spring 2017 for indications ovarian cancer & metastatic breast cancer; 20170301; 20170630; http://stocktwits.com/message/77020751

8) MICT – Micronet Enertec Technologies Inc – Trading Below Cash
a. Buy at < ~ $1.12
b. Sell at >~ $1.58

9) PRTO – Proteon Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $1.55
b. Sell at >~ $2.60
c. Catalysts:
2. A new clinical trial … hopes to enroll 500 before the end of 2017; 20170317; 20171231; http://www.bizjournals.com/kansascity/news/2017/03/17/proteon-therapeutics-vonapanitase-new-stage3-trial.html?ana=yahoo
3. Phase 3 enrollment to be completed 1Q 2017. Data due 2Q 2018. – Vonapanitase (PRT-201) PATENCY-2 – Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) – Phase 3; 20180401; 20180630; http://ir.proteontherapeutics.com/phoenix.zhtml?c=253625&p=irol-newsArticle&ID=2229192

10) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.17
b. Sell at >~ $2.45

11) DMTX – Dimension Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $1.65
b. Sell at >~ $2.20

12) SPRT – Support.com, Inc. – Trading Below Cash
a. Buy at < ~ $2.00
b. Sell at >~ $2.64

13) OPHT – Ophthotech Corp
a. Buy at < ~ $3.24
b. Sell at >~ $4.18
c. Catalysts:
1. After the Fovista trial with Avastin/Eylea is finished (some time in 1H17); 20170101; 20170630; https://seekingalpha.com/article/4057593-buy-ophthotech-get-cash-zimura-free
2. The catalyst would be an interim analysis of the Zimura Phase 2/3 trial which should occur some time between 2H2017 and 2H2018; 20170701; 20181231; https://seekingalpha.com/article/4057593-buy-ophthotech-get-cash-zimura-free

14) TROV – TrovaGene Inc – Trading Below Cash
a. Buy at < ~ $0.95
b. Sell at >~ $1.50

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 04/03/2017 - 04/07/2017, and Why?

[Michael DeVries]

20 Stock-Investing Tips => http://news.morningstar.com/classroom2/course.asp?docId=145666&page=1&CN=sample

Thank you to Sonya M. Seybold for sharing this article / course / these Tips with us all!

[Michael DeVries]

Building Your Trading Resilience => http://traderfeed.blogspot.com/2017/04/building-your-trading-resilience.html

I would Love to hear what you all think about any of those articles, ok?

I hope this all helps and Have a Great Day!

– Michael S. DeVries

[Michael DeVries]

Please find the Stock Pickers that I Follow on Twitter at: https://twitter.com/MichaelSDeVries/lists/stockpickers

Please find the Stock Traders that I follow on StockTwits at: https://stocktwits.com/MichaelSDeVries/following

Please find the Seeking Alpha authors that I follow at: https://seekingalpha.com/user/29420215/following

I hope this all helps! Good Luck! and Have a Great Day!

– Michael S. DeVries

[Michael DeVries]

How does one approach a, potentially large, company with an idea for a new product or significant improvement to one of their products in a way that both parties mutually benefit and profit from it?
… and so they can’t/don’t just “steal it for themselves”?

Do you have to get it patented first?

… and if so, then isn’t that difficult if it is still just an idea / in the conceptual stage?

Any and all responses would be Most Appreciated!

Thank you (in advance) for your responses and help in these regards and Have a Great Day!

– Michael S. DeVries

P.S. V.I.B.E.S. participants may see an example of such an idea at: https://goo.gl/k99XrR

[Michael DeVries]

Here’s another IMHO Must Read Article …

When Frustration Becomes Self-Abuse: How We Can Undercut–And Rebuild–Our Own Success =>

https://www.forbes.com/sites/brettsteenbarger/2017/03/26/when-frustration-becomes-self-abuse-how-we-can-undercut-and-rebuild-our-own-success/#b8e936730b5c

I hope this helps! Good Luck! and Have a Great Day!

– Michael S. DeVries

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 03/27/2017 – 03/31/2017:

1) GALE – Galena Biopharma Inc
a. Buy at < ~ $0.53
b. Sell at >~ $3.15

2) GNMX – Medgenics Inc
a. Buy at < ~ $1.50
b. Sell at >~ $4.00
c. Catalysts:
1. Multiple trails to complete / Catalysts by EOY 2017; 20170321; 20171231; http://aevigenomics.com/c/pipeline/index.php

3) TKAI – Tokai Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $0.73
b. Sell at >~ $1.80
c. Catalysts:
1. Merger with Otic Pharma Ltd; 20170101; 20170630; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5
2. Merger may be terminated if the Otic Transaction is not consummated by April 30, 2017; 20170301; 20170430; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5

4) NVGN – Novogen Limited (ADR)
a. Buy at < ~ $1.36
b. Sell at >~ $3.22
c. Catalysts:
1. Cantrixil started phase 1 clinic late last year.; 20161231; ; http://stocktwits.com/message/78192678
2. Anisina finishing up preclinical. Waiting on tox report. Trilexium is preclinical.; 20170101; ; http://stocktwits.com/message/78192678
3. GDC-0084 in phase 2 clinic sometime this year.; 20170301; 20171231; http://stocktwits.com/message/78192678

5) CYCC – Cyclacel Pharmaceuticals Inc
a. Buy at < ~ $3.15
b. Sell at >~ $5.60
c. Catalysts:
1. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
2. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3
3. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11

6) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $1.65
b. Sell at >~ $2.50
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. “@PeyoteBetting Hopefully a permission from EMA for sale of Paclical in Europe. Meeting scheduled in March”; 20170301; 20170331;
3. European approvals expected during spring 2017 for indications ovarian cancer & metastatic breast cancer; 20170301; 20170630; http://stocktwits.com/message/77020751

7) MICT – Micronet Enertec Technologies Inc – Trading Below Cash
a. Buy at < ~ $1.14
b. Sell at >~ $1.58

8) PRTO – Proteon Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $1.55
b. Sell at >~ $2.60
c. Catalysts:
1. Phase 3 enrollment to be completed 1Q 2017. Data due 2Q 2018. – Vonapanitase (PRT-201) PATENCY-2 – Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) – Phase 3; 20170101; 20170331; http://ir.proteontherapeutics.com/phoenix.zhtml?c=253625&p=irol-newsArticle&ID=2229192
3. Phase 3 enrollment to be completed 1Q 2017. Data due 2Q 2018. – Vonapanitase (PRT-201) PATENCY-2 – Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) – Phase 3; 20180401; 20180630; http://ir.proteontherapeutics.com/phoenix.zhtml?c=253625&p=irol-newsArticle&ID=2229192
4. A new clinical trial … hopes to enroll 500 before the end of 2017; 20170317; 20171231; http://www.bizjournals.com/kansascity/news/2017/03/17/proteon-therapeutics-vonapanitase-new-stage3-trial.html?ana=yahoo

9) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.17
b. Sell at >~ $2.45

10) SPRT – Support.com, Inc. – Trading Below Cash
a. Buy at < ~ $2.00
b. Sell at >~ $2.64

11) GENE – Genetic Technologies Limited (ADR)
a. Buy at < ~ $1.04
b. Sell at >~ $2.70
c. Catalysts:
1. Genetic Technologies is expected to post its validation study for the test within six months; 20170101; 20170630; http://seekingalpha.com/article/4033099-genetic-technologies-catalysts-tremendous-upside

12) TROV – TrovaGene Inc – Trading Below Cash
a. Buy at < ~ $0.95
b. Sell at >~ $1.50

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 03/27/2017 - 03/31/2017, and Why?

[Michael DeVries]

What do you all think about Entropica?

What do you think about the application / use for Entropica in automated / artificially intelligent stock trading?

To Be Continued …

References:

1. http://www.entropica.com/
2. Link to Dr. Alexander D. Wissner-Gross‘s TED talk about Entropica => http://on.ted.com/WissnerGross
3. https://phys.org/news/2013-04-emergence-complex-behaviors-causal-entropic.html

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 03/20/2017 – 03/24/2017:

1) GALE – Galena Biopharma Inc
a. Buy at < ~ $0.53
b. Sell at >~ $3.15

2) TKAI – Tokai Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $0.73
b. Sell at >~ $1.80
c. Catalysts:
1. Merger with Otic Pharma Ltd; 20170101; 20170630; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5
2. Merger may be terminated if the Otic Transaction is not consummated by April 30, 2017; 20170301; 20170430; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5

3) CYCC – Cyclacel Pharmaceuticals Inc
a. Buy at < ~ $3.42
b. Sell at >~ $5.60
c. Catalysts:
1. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
2. Q4 2016 Cyclacel Pharmaceuticals Inc Earnings Release (Estimated)
-; 20170322; 20170322; https://www.google.com/finance?q=CYCC
3. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
4. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3

4) OASM – Oasmia Pharmaceutical AB – American Depositary Shares
a. Buy at < ~ $1.65
b. Sell at >~ $2.50
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. “@PeyoteBetting Hopefully a permission from EMA for sale of Paclical in Europe. Meeting scheduled in March”; 20170301; 20170331;
3. European approvals expected during spring 2017 for indications ovarian cancer & metastatic breast cancer; 20170301; 20170630; http://stocktwits.com/message/77020751

5) MICT – Micronet Enertec Technologies Inc – Trading Below Cash
a. Buy at < ~ $1.14
b. Sell at >~ $1.58

6) PRTO – Proteon Therapeutics Inc – Trading Below Cash
a. Buy at < ~ $1.58
b. Sell at >~ $2.60
c. Catalysts:
1. A new clinical trial … hopes to enroll 500 before the end of 2017; 20170317; 20171231; http://www.bizjournals.com/kansascity/news/2017/03/17/proteon-therapeutics-vonapanitase-new-stage3-trial.html?ana=yahoo
2. Phase 3 enrollment to be completed 1Q 2017. Data due 2Q 2018. – Vonapanitase (PRT-201) PATENCY-2 – Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) – Phase 3; 20170101; 20170331; http://ir.proteontherapeutics.com/phoenix.zhtml?c=253625&p=irol-newsArticle&ID=2229192
3. Phase 3 enrollment to be completed 1Q 2017. Data due 2Q 2018. – Vonapanitase (PRT-201) PATENCY-2 – Chronic kidney disease (CKD) patients undergoing surgical placement of an arteriovenous fistula (AVF) – Phase 3; 20180401; 20180630; http://ir.proteontherapeutics.com/phoenix.zhtml?c=253625&p=irol-newsArticle&ID=2229192
4. Proteon Therapeutics to Present at the Oppenheimer 27th Annual Healthcare Conference March 22nd; 20170322; 20170322; http://finance.yahoo.com/news/proteon-therapeutics-present-oppenheimer-27th-115500386.html

7) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.17
b. Sell at >~ $2.45

8) GENE – Genetic Technologies Limited (ADR)
a. Buy at < ~ $1.04
b. Sell at >~ $2.70
c. Catalysts:
1. Genetic Technologies is expected to post its validation study for the test within six months; 20170101; 20170630; http://seekingalpha.com/article/4033099-genetic-technologies-catalysts-tremendous-upside

9) TROV – TrovaGene Inc – Trading Below Cash
a. Buy at < ~ $1.25
b. Sell at >~ $1.50

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 03/20/2017 - 03/24/2017, and Why?

[Michael DeVries]

Please find included below some of the Trading Articles that I would Highly Recommend:

1. Exceptional investing returns are a product of these two steps => http://realmoney.thestreet.com/articles/03/11/2017/2-steps-superior-returns?cm_ven_int=homepage-featured
2. Surviving the Continuous Chain of Disappointments => http://www.collaborativefund.com/blog/surviving-the-continuous-chain-of-disappointments/

I would Love to hear what you all think about any of those articles, ok?

I hope this all helps and Have a Great Day!

– Michael S. DeVries

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 03/13/2017 – 03/17/2017:

1) TKAI – Tokai Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $0.73
b. Sell at >~ $1.80
c. Catalysts:
1. Merger with Otic Pharma Ltd; 20170101; 20170630; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5
2. Merger may be terminated if the Otic Transaction is not consummated by April 30, 2017; 20170301; 20170430; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5

2) CYCC – Cyclacel Pharmaceuticals Inc
a. Buy at < ~ $3.42
b. Sell at >~ $5.60
c. Catalysts:
1. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
2. Q4 2016 Cyclacel Pharmaceuticals Inc Earnings Release (Estimated)
-; 20170322; 20170322; https://www.google.com/finance?q=CYCC
3. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
4. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3

3) OASM – Oasmia Pharmaceutical AB
a. Buy at < ~ $1.65
b. Sell at >~ $2.50
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. “@PeyoteBetting Hopefully a permission from EMA for sale of Paclical in Europe. Meeting scheduled in March”; 20170301; 20170331;
3. European approvals expected during spring 2017 for indications ovarian cancer & metastatic breast cancer; 20170301; 20170630; http://stocktwits.com/message/77020751

4) MICT – Micronet Enertec Technologies Inc – Trading Below Cash
a. Buy at < ~ $1.14
b. Sell at >~ $1.58

5) TISA – Top Image Systems Ltd.
a. Buy at < ~ $1.17
b. Sell at >~ $2.45
c. Catalysts:
1. Top Image Systems to Present at 29th Annual ROTH Conference on March 14th, 2017; 20170314; 20170314; http://finance.yahoo.com/news/top-image-systems-present-29th-140000745.html

6) GENE – Genetic Technologies Limited (ADR)
a. Buy at < ~ $1.04
b. Sell at >~ $2.70
c. Catalysts:
1. Genetic Technologies is expected to post its validation study for the test within six months; 20170101; 20170630; http://seekingalpha.com/article/4033099-genetic-technologies-catalysts-tremendous-upside

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 03/13/2017 - 03/17/2017, and Why?

[Michael DeVries]

What do you all think about BigML?

If you have used BigML, then:

• What kinds of machine learning solutions did you develop using BigML?
• How easy to use did you find BigML?
• What Lessons Learned regarding BigML would you be willing and able to share with us all?

What other (ideally Free) machine learning tools or platforms have you used?

• Which do you like Best and Why?
• What are their Pro’s and Con’s vs. BigML?

Thank you for your responses and help in these regards and Have a Great Day!

Michael S. DeVries

To Be Continued …

References:

https://bigml.com/

[Michael DeVries]

The following are the Stock Symbols on my Watchlist to Buy if/when they bottom out at the Buy at Price Targets listed below for the Week of 03/06/2017 – 03/10/2017:

1) TKAI – Tokai Pharmaceuticals Inc – Trading Below Cash
a. Buy at < ~ $0.73
b. Sell at >~ $1.80
c. Catalysts:
1. Merger with Otic Pharma Ltd; 20170101; 20170630; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5
2. Merger may be terminated if the Otic Transaction is not consummated by April 30, 2017; 20170301; 20170430; http://seekingalpha.com/filing/3366062#D307733DPREM14A_HTM_TOC307733_5

2) TRVN – Trevena Inc
a. Buy at < ~ $3.70
b. Sell at >~ $8.00
c. Catalysts:
1. Q4 2016 Trevena Inc Earnings Release (Estimated)
-; 20170307; 20170307; https://www.google.com/finance?q=TRVN

3) CYCC – Cyclacel Pharmaceuticals Inc
a. Buy at < ~ $3.42
b. Sell at >~ $5.60
c. Catalysts:
1. A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors; 20180701; 20180731; https://www.clinicaltrials.gov/ct2/show/NCT00999401?term=Cyclacel&recr=Open&rank=2
2. Q4 2016 Cyclacel Pharmaceuticals Inc Earnings Release (Estimated)
-; 20170322; 20170322; https://www.google.com/finance?q=CYCC
3. Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23) Phase 2; 20190701; 20190731; https://www.clinicaltrials.gov/ct2/show/NCT01253460?term=Cyclacel&rank=11
4. Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation (ROSCO-CF); 20180801; 20181031; https://www.clinicaltrials.gov/ct2/show/NCT02649751?term=Cyclacel&recr=Open&rank=3

4) OASM – Oasmia Pharmaceutical AB
a. Buy at < ~ $1.70
b. Sell at >~ $2.50
c. Catalysts:
1. 1. Doxophos appr. Russia. 2. Apealea appr. Europe (ovarian cancer & metastatic breast cancer) 3. Comm. agreement Apealea 4. Positive cash flow 5. Several license agreements of nano technology XR17 (similar to Celator) and lots more to come; 20170101; 20171231; https://stocktwits.com/swedetrader/message/76192391
2. “@PeyoteBetting Hopefully a permission from EMA for sale of Paclical in Europe. Meeting scheduled in March”; 20170301; 20170331;

5) MICT – Micronet Enertec Technologies Inc
a. Buy at < ~ $1.14
b. Sell at >~ $1.58

What do you think about these Stock Picks to Buy at these Price Targets?

What other Stock Symbols do you all think are the Best Stocks <~ $10 to Buy next week, 03/06/2017 - 03/10/2017, and Why?

[Author]

Posts